DEFA14A: Catheter Precision Sets Record Date for Special Meeting

Catheter Precision announces a September 10th record date for its October 10th special meeting of stockholders to approve increasing authorized shares and ratify the auditor.

Summary

• Catheter Precision has set September 10, 2025, as the record date for a special meeting of stockholders to be held on October 10, 2025.
• The company is seeking stockholder approval to amend its Certificate of Incorporation to increase the number of authorized shares of common stock.
• Stockholders will also be asked to ratify the appointment of WithumSmith+Brown, PC as the company's independent auditor for the fiscal year 2026.
• Additional details will be available in the preliminary proxy statement to be filed with the SEC on September 4, 2025.

Sentiment

Score: 5

Explanation: The announcement is neutral, outlining procedural steps for an upcoming meeting.

Positives

• The company is proactively addressing its capital structure by seeking to increase authorized shares.
• The company is seeking to ratify the appointment of an independent auditor, which is a standard corporate governance practice.

Risks

• The company's expectations and beliefs regarding the matters to be addressed at the special meeting may not materialize.
• Actual outcomes and results may differ materially from those contemplated by forward-looking statements due to uncertainties, risks, and changes in circumstances.
• Timing of the meeting, the business to be conducted at the meeting, and the timing of related SEC filings may also be impacted by market developments or changes in business plans.

Future Outlook

The company's future outlook is subject to risks and uncertainties, and actual results may differ materially from those anticipated in forward-looking statements. The company does not assume any obligation to update these statements.

Management Comments

• Catheter Precision is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.

Industry Context

This announcement reflects standard corporate governance procedures for publicly traded companies, including seeking stockholder approval for significant corporate actions and auditor ratification. This is in the context of the medical device industry and specifically the cardiac electrophysiology market.

Stakeholder Impact

• Shareholders: Will be asked to vote on increasing authorized shares and ratifying the auditor.
• Auditor: WithumSmith+Brown, PC is up for ratification as the independent auditor for fiscal year 2026.

Next Steps

• File the preliminary proxy statement with the SEC.
• Solicit proxies from stockholders for the special meeting.
• Conduct the special meeting of stockholders on October 10, 2025.

Key Dates

Recommendation

The company is seeking approval for routine corporate matters. While the increase in authorized shares could signal future capital raising activities, the announcement itself does not warrant a change in investment recommendation.

Keywords

Catheter Precision, Special Meeting, Stockholders, Authorized Shares, Auditor Ratification, Cardiac Electrophysiology, Medical Device